Ayurvedic management of katigraha( lumbar spondylosis)

â??Randomized Controlled Trial on Synergistic Effect of Vatari Guggulu, Panchatikta Ksheerbasti and Katibasti in Katigrah with Special Reference to Lumbar Spondylosis.â??

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048545

Enrollment

Registered

2022-12-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M199- Osteoarthritis, unspecified site Health Condition 2: M472- Other spondylosis with radiculopathy

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex aged between 18- 70 years irrespective of caste, religion, socioeconomic & educational status. 2.The Roland and Morris disability questionnaire; if RDQ score > 5 3.Radiological degenerative changes in Lumbar spine. 4.Patients having sign and symptoms of Katigrah according to classics. 5.Patient willing and able to participate in the study. 6.Chronic low back pain more than three months.

Exclusion criteria

Exclusion criteria: 1.History of any fracture of vertebral joint/ surgical/ diagnostic intervention with reference to affected joints will be excluded. 2.Gross disability in performing daily normal routine i.e. bedridden patient or confined to a wheelchair will be excluded. 3.Patient with co-morbidities such as gouty arthritis, rheumatoid arthritis or psoriatic arthritis and tubercular arthritis. 4.Patient with any deformity of hip or back altering the gait and posture of the patient, ankylosing spondylitis, pelvic inflammatory disorders. 5.Patient with uncontrolled hypertension and uncontrolled diabetes will be ruled out. 6.Patient with evidence of malignancy. 7.Patient on prolonged (>=6weeks) medication with corticosteroids, non-steroidal anti-inflammatory drug, antidepressants, anti-cholinergic etc. or any drugs that may influence on the outcome of the study. 8.Pregnant / lactating women.

Design outcomes

Primary

Measure	Time frame
1.To Evaluate the synergistic effect of Vatari Guggulu, Panchatikta Kshira Basti along with Kati Basti particularly on the Rolland and Morris disability questionnaire and clinical features of Katigrah with special reference to Lumbar Spondylosis. 2.To compare the effect of Vatari Guggulu, Panchatikta Kshira Basti along with Kati Basti with Erandamula Ghanavati , Panchatikta Kshira Basti along with Kati Basti particularly on Rolland Morris Index. Timepoint: 35 Days	—

Measure

Time frame

1.To Evaluate the synergistic effect of Vatari Guggulu, Panchatikta Kshira Basti along with Kati Basti particularly on the Rolland and Morris disability questionnaire and clinical features of Katigrah with special reference to Lumbar Spondylosis. 2.To compare the effect of Vatari Guggulu, Panchatikta Kshira Basti along with Kati Basti with Erandamula Ghanavati , Panchatikta Kshira Basti along with Kati Basti particularly on Rolland Morris Index. Timepoint: 35 Days

—

Secondary

Measure	Time frame
WOMAC Score VAS Score Timepoint: 35 Days	—

Countries

India

Contacts

Public ContactRamraj singh

Goverment Ayurved College, Nagpur

jayant.gulhane.62.6@gmail.com9822922399

Outcome results